Metabolomics analysis reveals insights into biochemical mechanisms of mental stress-induced left ventricular dysfunction

被引:16
作者
Boyle, Stephen H. [1 ]
Matson, Wayne R. [2 ]
Velazquez, Eric J. [3 ]
Samad, Zainab [3 ]
Williams, Redford B., Jr. [1 ]
Sharma, Swati [2 ]
Thomas, Beena [2 ]
Wilson, Jennifer L. [1 ]
O'Connor, Christopher [3 ]
Jiang, Wei [1 ,3 ]
机构
[1] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA
[2] Counterpoint Hlth Solut Inc, Dept Syst Biochem, Bedford, MA USA
[3] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
关键词
Left ventricular dysfunction; Mental stress; Metabolomics; INDUCED MYOCARDIAL-ISCHEMIA; CORONARY-ARTERY-DISEASE; PSYCHOPHYSIOLOGICAL INVESTIGATIONS; PSYCHOLOGICAL STRESS; S-ADENOSYLMETHIONINE; URIC-ACID; DEPRESSION; KYNURENINE; RECEPTORS; SEROTONIN;
D O I
10.1007/s11306-014-0718-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mental stress induced left ventricular dysfunction (LVD) has been associated with a greater risk of adverse events in coronary heart disease (CHD) patients independent of conventional risk indicators. The underlying biochemical mechanisms of this cardiovascular condition are poorly understood. Our objective was to use metabolomics technology to identify biochemical changes that co-occur with mental stress-induced LVD in patients with clinically stable CHD. Participants were adult CHD patients who were recruited for mental stress-induced myocardial ischemia screening. For this study, we randomly selected 30 patients representing the extremes of the mental stress-induced left ventricular ejection fraction (LVEF) change distribution; 15 who showed LVD (i.e. LVEF reduction a parts per thousand yen5) and 15 who showed a normal left ventricular response (NLVR; i.e. a LVEF increase of a parts per thousand yen5) to three mental stressors. An electrochemistry based metabolomics platform was used to profile pre- and post-stress serum samples yielding data for 22 known compounds, primarily within the tyrosine, tryptophan, purine and methionine pathways. There were significant stress-induced changes in several compounds. A comparison between the NLVR and LVD groups showed significant effects for kynurenine (p = .036, N-acetylserotonin (p = .054), uric acid (p = .015), tyrosine (p = .019) and a trend for methionine (p = .065); the NLVR group showed a significantly greater stress-induced reduction in all of those compounds compared to the LVD group. Many of these biochemicals have been implicated in other stress-related phenomena and are plausible candidates for mechanisms underlying LVD in response to mental stress.
引用
收藏
页码:571 / 582
页数:12
相关论文
共 58 条
  • [21] KAGAN BL, 1990, AM J PSYCHIAT, V147, P591
  • [22] Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease
    Kanellis, J
    Kang, DH
    [J]. SEMINARS IN NEPHROLOGY, 2005, 25 (01) : 39 - 42
  • [23] Prognostic value of mental stress testing in coronary artery disease
    Krantz, DS
    Santiago, HT
    Kop, WJ
    Merz, CNB
    Rozanski, A
    Gottdiener, JS
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (11) : 1292 - 1297
  • [24] Kristal Bruce S, 2002, Methods Mol Biol, V186, P185
  • [25] Effect of mental stress on left ventricular ejection fraction and its relationship to the severity of coronary artery disease
    Kuroda, T
    Kuwabara, Y
    Watanabe, S
    Nakaya, J
    Hasegawa, R
    Shikama, T
    Matsuno, K
    Mikami, Y
    Fujii, K
    Saito, T
    Masuda, Y
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (12) : 1760 - 1767
  • [26] Altered uric acid levels and disease states
    Kutzing, Melinda K.
    Firestein, Bonnie L.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 324 (01) : 1 - 7
  • [27] Depression as a risk factor for coronary artery disease: Evidence, mechanisms, and treatment
    Lett, HS
    Blumenthal, JA
    Babyak, MA
    Sherwood, A
    Strauman, T
    Robins, C
    Newman, MF
    [J]. PSYCHOSOMATIC MEDICINE, 2004, 66 (03): : 305 - 315
  • [28] CARDIOVASCULAR DOPAMINE-RECEPTORS - PHYSIOLOGICAL, PHARMACOLOGICAL AND THERAPEUTIC IMPLICATIONS
    LOKHANDWALA, MF
    BARRETT, RJ
    [J]. JOURNAL OF AUTONOMIC PHARMACOLOGY, 1982, 2 (03): : 189 - 215
  • [29] MATSON WR, 1984, CLIN CHEM, V30, P1477
  • [30] MCCALL RB, 1994, PHARMACOL REV, V46, P231